E. Romano, M. Manetti, S. Guiducci, C. Ceccarelli, Y. Allanore et al., The genetics of systemic sclerosis: an update, Clin Exp Rheumatol, vol.29, pp.75-86, 2011.

E. Leroy, T. Medsger, and . Jr, Criteria for the classification of early systemic sclerosis, J Rheumatol, vol.28, pp.1573-1576, 2001.

T. Novobrantseva, G. Majeau, A. Amatucci, S. Kogan, I. Brenner et al., Attenuated liver fibrosis in the absence of B cells, Journal of Clinical Investigation, vol.115, issue.11, pp.3072-3082, 2005.
DOI : 10.1172/JCI24798DS1

K. Komura, K. Yanaba, M. Horikawa, F. Ogawa, M. Fujimoto et al., CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model, Arthritis & Rheumatism, vol.176, issue.11, pp.193574-3584, 2008.
DOI : 10.1002/art.23995

M. Kraaij and J. Van-laar, The role of B cells in systemic sclerosis, Biologics, vol.2, pp.389-395, 2008.

M. Whitfield, D. Finlay, J. Murray, O. Troyanskaya, J. Chi et al., Systemic and cell type-specific gene expression patterns in scleroderma skin, Proceedings of the National Academy of Sciences, vol.100, issue.21, pp.12319-12324, 2003.
DOI : 10.1073/pnas.1635114100

M. Duncan and B. Berman, Stimulation of Collagen and Glycosaminoglycan Production in Cultured Human Adult Dermal Fibroblasts by Recombinant Human Interleukin 6, Journal of Investigative Dermatology, vol.97, issue.4, pp.686-692, 1991.
DOI : 10.1111/1523-1747.ep12483971

S. Sato, M. Hasegawa, and K. Takehara, Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis, Journal of Dermatological Science, vol.27, issue.2, pp.140-146, 2001.
DOI : 10.1016/S0923-1811(01)00128-1

F. Saito, S. Tasaka, K. Inoue, K. Miyamoto, Y. Nakano et al., Role of Interleukin-6 in Bleomycin-Induced Lung Inflammatory Changes in Mice, American Journal of Respiratory Cell and Molecular Biology, vol.38, issue.5
DOI : 10.1165/rcmb.2007-0299OC

F. Verrecchia, J. Laboureau, O. Verola, N. Roos, R. Porcher et al., Skin involvement in scleroderma--where histological and clinical scores meet, Rheumatology, vol.46, issue.5, pp.833-841, 2007.
DOI : 10.1093/rheumatology/kel451
URL : https://hal.archives-ouvertes.fr/inserm-00166113

F. Mackay and P. Schneider, Cracking the BAFF code, Nature Reviews Immunology, vol.173, issue.7, pp.491-502, 2009.
DOI : 10.1038/nri2572

S. Kalled, The role of BAFF in immune function and implications for autoimmunity, Immunological Reviews, vol.167, issue.1, pp.43-54, 2005.
DOI : 10.1097/00002030-200309050-00018

F. Mackay, S. Woodcock, P. Lawton, C. Ambrose, M. Baetscher et al., Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations, The Journal of Experimental Medicine, vol.51, issue.11, pp.1697-1710, 1999.
DOI : 10.1038/32588

T. Matsushita, M. Fujimoto, M. Hasegawa, C. Tanaka, S. Kumada et al., Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF, J Rheumatol, vol.34, pp.2056-2062, 2007.

T. Matsushita, M. Hasegawa, K. Yanaba, M. Kodera, K. Takehara et al., Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes, Arthritis & Rheumatism, vol.48, issue.1, pp.192-201, 2006.
DOI : 10.1002/art.21526

L. Ng, A. Sutherland, R. Newton, F. Qian, T. Cachero et al., B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating TandBcells, pp.807-817, 2004.

W. Kim, S. Min, M. Cho, K. Hong, Y. Shin et al., Elevated matrix metalloproteinase-9 in patients with systemic sclerosis, Arthritis Research & Therapy, vol.7, issue.1, pp.71-79, 2005.
DOI : 10.1186/ar1454

J. Henault, G. Robitaille, J. Senecal, and R. Y. , DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti???topoisomerase I autoantibodies from systemic sclerosis patients, Arthritis & Rheumatism, vol.86, issue.3, pp.963-973, 2006.
DOI : 10.1002/art.21646

S. Sato, M. Fujimoto, M. Hasegawa, K. Takehara, and T. Tedder, Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis, Molecular Immunology, vol.41, issue.12, pp.1123-1133, 2004.
DOI : 10.1016/j.molimm.2004.06.025

S. Sato, M. Hasegawa, M. Fujimoto, T. Tedder, and K. Takehara, Quantitative Genetic Variation in CD19 Expression Correlates with Autoimmunity, The Journal of Immunology, vol.165, issue.11, pp.6635-6643, 2000.
DOI : 10.4049/jimmunol.165.11.6635

S. Sato, M. Fujimoto, M. Hasegawa, and K. Takehara, Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells, Arthritis & Rheumatism, vol.46, issue.6, pp.1918-1927, 2004.
DOI : 10.1002/art.20274

C. Chizzolini, Y. Parel, D. Luca, C. Tyndall, A. Akesson et al., Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor ??, Arthritis & Rheumatism, vol.278, issue.Suppl 1, pp.2593-2604, 2003.
DOI : 10.1002/art.11129

C. Chizzolini, R. Rezzonico, C. Ribbens, D. Burger, F. Wollheim et al., Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: Different sensitivity to inhibition between systemic sclerosis and control fibroblasts, Arthritis & Rheumatism, vol.23, issue.11, pp.2039-2047, 1998.
DOI : 10.1002/1529-0131(199811)41:11<2039::AID-ART20>3.0.CO;2-1

K. Kondo, T. Okada, T. Matsui, S. Kato, K. Date et al., ESTABLISHMENT AND CHARACTERIZATION OF A HUMAN B CELL LINE FROM THE LUNG TISSUE OF A PATIENT WITH SCLERODERMA; EXTRAORDINARY HIGH LEVEL OF IL-6 SECRETION BY STIMULATED FIBROBLASTS, Cytokine, vol.13, issue.4, pp.220-226, 2001.
DOI : 10.1006/cyto.2000.0822

D. Abraham, T. Krieg, J. Distler, and O. Distler, Overview of pathogenesis of systemic sclerosis, Rheumatology, vol.48, issue.Supplement 3, pp.3-7, 2009.
DOI : 10.1093/rheumatology/ken481

S. Young-min, C. Beeton, R. Laughton, T. Plumpton, S. Bartram et al., Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls, Ann Rheum Dis, vol.60, pp.846-851, 2001.

J. Varga and D. Abraham, Systemic sclerosis: a prototypic multisystem fibrotic disorder, Journal of Clinical Investigation, vol.117, issue.3, pp.557-567, 2007.
DOI : 10.1172/JCI31139

T. Kirk, M. Mark, C. Chua, B. Chua, and M. Mayes, Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1

K. Yoshimoto, M. Tanaka, M. Kojima, Y. Setoyama, H. Kameda et al., Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sj??gren's syndrome, Arthritis Research & Therapy, vol.13, issue.5, p.170, 2011.
DOI : 10.1046/j.1365-2249.2002.01869.x

P. Couture, J. Paradis-massie, N. Oualha, and G. Thibault, Adhesion and transcellular migration of neutrophils and B lymphocytes on fibroblasts, Experimental Cell Research, vol.315, issue.13, pp.2192-2206, 2009.
DOI : 10.1016/j.yexcr.2009.04.013

S. Bosello, D. Santis, M. Lama, G. Spano, C. Angelucci et al., B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial, Arthritis Research & Therapy, vol.12, issue.2, p.54, 2010.
DOI : 10.1186/ar2965

D. Daoussis, S. Liossis, A. Tsamandas, C. Kalogeropoulou, A. Kazantzi et al., Is There a Role for B-cell Depletion as Therapy for Scleroderma? A Case Report and Review of the Literature, Seminars in Arthritis and Rheumatism, vol.40, issue.2, pp.127-136, 2010.
DOI : 10.1016/j.semarthrit.2009.09.003

D. Daoussis, S. Liossis, A. Tsamandas, C. Kalogeropoulou, F. Paliogianni et al., Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis, Clin Exp Rheumatol, vol.30, pp.17-22, 2011.

M. Hasegawa, Y. Hamaguchi, K. Yanaba, J. Bouaziz, J. Uchida et al., B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic Sclerosis, The American Journal of Pathology, vol.169, issue.3, pp.954-966, 2006.
DOI : 10.2353/ajpath.2006.060205

T. Matsushita, M. Fujimoto, M. Hasegawa, Y. Matsushita, K. Komura et al., BAFF Antagonist Attenuates the Development of Skin Fibrosis in Tight-Skin Mice, Journal of Investigative Dermatology, vol.127, issue.12, pp.2772-2780, 2007.
DOI : 10.1038/sj.jid.5700919